Loading…
A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology
Purpose To establish whether the expression of markers of cell differentiation (CK7, CK14, CK20, GATA3), apoptosis (p53), proliferation (Ki67, STAG2) and peri-tumoural lymphocytes (CD3, CD8), provides specific information about urothelial carcinogenesis in neuro-urological patients with bladder canc...
Saved in:
Published in: | World journal of urology 2022-08, Vol.40 (8), p.1939-1947 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Purpose
To establish whether the expression of markers of cell differentiation (CK7, CK14, CK20, GATA3), apoptosis (p53), proliferation (Ki67, STAG2) and peri-tumoural lymphocytes (CD3, CD8), provides specific information about urothelial carcinogenesis in neuro-urological patients with bladder cancer (NBC).
Methods
Tissue samples from NBC were retrieved from 15 centres in France and compared to control samples from non neuro-urological patients with bladder cancer (NNBC) and from neuro-urological patients without bladder cancer (NB). The expression of CK7, CK14, CK20, GATA3, p53, Ki67, STAG2, CD3 and CD8 markers was analysed using immunohistochemistry of tissue microarray sections.
Results
Overall, tissue samples from 124 patients were included in the study (
n
= 72 NBC,
n
= 26 NNBC and
n
= 26 NB). Muscle invasive bladder cancer (MIBC) was found in 52 NBC patients (72.2%) and squamous cell differentiation in 9 (12.5%). In NBC samples, the expression of CK20 and GATA3 was significantly more frequent in NMIBC compared to MIBC (
p
= 0.015 and
p
= 0.004, respectively). CK20 and GATA3 were significantly more expressed in NBC compared to NNBC (
p
|
---|---|
ISSN: | 1433-8726 0724-4983 1433-8726 |
DOI: | 10.1007/s00345-022-03942-3 |